<DOC>
	<DOCNO>NCT01023464</DOCNO>
	<brief_summary>To evaluate effect FID 114657 tear film break-up time dry eye patient .</brief_summary>
	<brief_title>Tear Film Break-Up Time Evaluation FID 114657</brief_title>
	<detailed_description />
	<mesh_term>Emollients</mesh_term>
	<criteria>1 . The informed consent document HIPAA privacy document must read , sign dated patient legally authorize representative conducting procedure . 2 . Patients ( minimum age 18 ) dry eye . Criteria diagnosis must include follow characteristic Visit 1 ( Screening ) : Patients ' selfassessment dry eye status ( answer least Some time question , `` How often eye felt dry enough want use eye drop ? `` ) ; TFBUT &lt; 5 second least one eye ; &gt; Grade 1 Meibomian Gland Expression eye ; Evidence miss meibomian gland eye . 3 . Able willing follow study instruction . 4 . Patients must bestcorrected visual acuity 0.6 logMAR good eye assess use ETDRS chart Visit 1 . 5 . Patients must use topical ocular drop approximately 24 hour prior Visit 1 . 1 . History evidence ocular intraocular surgery either eye within past six month . 2 . History evidence serious ocular trauma either eye within past six month . 3 . Current punctal occlusion type ( e.g. , collagen plug , silicone plug ) . 4 . History intolerance hypersensitivity component study medication . 5 . History evidence epithelial herpes simplex keratitis ( dendritic keratitis ) ; vaccinia ; active recent varicella viral disease cornea and/or conjunctiva ; chronic bacterial disease cornea and/or conjunctiva and/or eyelid ; mycobacterial infection eye ; and/or fungal disease eye . 6 . Use concomitant topical ocular medication study period . 7 . Patients use systemic medication may contribute dry eye ( e.g . cold allergy medication , tricyclic antidepressant , hormone replacement therapy ) may enrol study unless stable dose regimen minimum 30 day prior Visit 1 . In addition , dose regimen must remain stable throughout study . 8 . Ocular condition conjunctival infection , iritis , ocular condition may preclude safe administration test article . 9 . Individuals unwilling discontinue contact lens wear study period . Contact lens wear must discontinue least one week prior Visit 1 . 10 . Enrollment investigator 's office staff , relative , member respective household ; enrollment one member household . 11 . Participation investigational drug device study within 30 day enter study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>tear film break-up time</keyword>
</DOC>